Telix Pharmaceuticals Limited American Depositary Shares TLX

Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.

• GlobeNewswire Inc. 20 sept

  Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

  Telix Pharmaceuticals has announced a strategic merger agreement to acquire ITM Isotope Technologies Munich for $1.65 billion upfront, with up to $700 million in contingent consideration. The merger combines Telix's therapeutic pipeline with ITM's world-leading radioisotope production capabilities and ITM-11 (177Lu-edotreotide), a Phase 3-completed candidate for neuroendocrine tumors. The combined entity is expected to generate over $1.3 billion in pro forma 2026 revenue and achieve positive EBITDA by 2027.

  

• GlobeNewswire Inc. 31 ago

  Telix Appoints David Gill as Chair

  Telix Pharmaceuticals announced that David Gill has been appointed as Chair of the Board, effective immediately. Gill, who joined as a Non-Executive Director in May 2026, brings over 35 years of life sciences executive experience, including expertise in radiopharmaceuticals, capital markets, and corporate strategy. He succeeds Dr. Mark Nelson, who served as interim Chair and will remain as a Non-Executive Director.

  

• GlobeNewswire Inc. 30 jul

  Telix H1 2026 Results: Investor Webcast Notification

  Telix Pharmaceuticals announced it will release its half-year financial results for June 30, 2026 on August 20, 2026, with an accompanying investor webcast and conference call. The company reported Q2 2026 revenue of US$247M with strong commercial momentum and pipeline progress across its radiopharmaceutical portfolio.

  

• GlobeNewswire Inc. 21 jul

  TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

  Telix Pharmaceuticals announced publication of ProstACT SELECT Phase 1 study results in peer-reviewed journal Cancers, demonstrating that 68Ga-PSMA-PET imaging can reliably identify patients suitable for TLX591-Tx therapy. The study showed TLX591-Tx achieved a median radiographic progression-free survival of 8.8 months with a manageable safety profile in advanced metastatic prostate cancer patients, supporting the ongoing Phase 3 ProstACT Global trial.

  

• GlobeNewswire Inc. 20 jul

  Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

  Telix Pharmaceuticals reported Q2 2026 group revenue of US$247 million (up 7% QoQ, 21% YoY) with Precision Medicine revenue reaching US$202 million (up 30% YoY). The company achieved key regulatory milestones including FDA alignment on TLX591-Tx Phase 3 trial progression and near-completion of BiPASS patient enrollment. FY 2026 revenue guidance remains on track to exceed US$1 billion. Telix also entered a strategic collaboration with Regeneron and completed a convertible bond refinancing.